Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Enrolling by invitation × Carboplatin × Endocrine × Clear all

Phase

Status

Completed 4 Recruiting 3 Active not recruiting 3 Withdrawn 1 Terminated 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2 Thoracic 1 NET 1 Gynecologic 1 Endocrine 1

Conditions

Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

somapacitan 1 irinotecan sucrosofate 1 PM 01183 1 Injections 1 Fluorodeoxyglucose F18 1 Diagnostic Self Evaluation 1 Carboplatin 1 Cabergoline 1 Bed Rest 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

National Health Research Institutes, Taiwan

Phase 1/2 Enrolling by invitation

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡